Gene-based association testing integrating xQTLs identifies candidate drug targets for Alzheimer's disease

Noah Lorincz-Comi[1,2], Wenqiang Song[1,2], & Feixiong Cheng[1,2*]

[1]Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA;
[2]Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. *Correspondence F.C. <chengf@ccf.org>

Cleveland Clinic Genome Center

Cleveland Clinic Lerner Research Institute

BACKGROUND

- Inferring risk genes using lead SNPs – i.e., those with the smallest AD association P-values – in neither powerful nor precise.
- Gene-based association testing overcomes these limitations, but current implementations of it have inflated Type I or II errors because they have not correctly specified the null distribution of the test statistic used to test the association null hypothesis.
- We provide the first closed-form expression of this null distribution, guaranteeing controlled Type I and II error of gene-based association tests.
- Integrating xQTL information in gene-based association testing can further improve power while providing causal inference under the assumption of no direct genetic effects on AD conditional on the xQTL phenotype, which is equivalent to the no horizontal pleiotropy assumption in MR (Mend. Rand.).



CONCLUSIONS

(1) Gene-based association testing integrating xQTLs can identify AD-associated genes with additional evidence of causality (2) *NTRK1* is a candidate druggable target for AD onset. (3) Future experimental studies are required to identify candidate drug targets for AD onset from our preliminary genome-wide screening.

ACKNOWLEDGEMENTS & REFERENCES

This work was supported by the National Institute on Aging (NIA) under Award Number U01AG073323, R01AG066707, R01AG084250, R56AG074001, R01AG076448, R01AG082118, RF1AG082211, and R21AG083003, and the National Institute of Neurological Disorders and Stroke (NINDS) under Award Number RF1NS133812, and the Alzheimer's Association award (ALZDISCOVERY-1051936) to F.C.

METHODS

Lead SNP-based inference of risk genes



SNP set-based inference of risk genes



$$H_0^B: \bigcap_{j=1}^{M_B} \beta_j = 0 \text{ vs } H_1^B: \bigcup_{j=1}^{M_B} \beta_j \neq 0 \text{ using } T_B = \sum_{j=1}^{M_B} \frac{\hat{\beta}_j^2}{\text{Var}(\beta_j)} \mid H_0^B \sim \Gamma(\alpha_B, \xi_B)$$

Integrating xQTLs in gene-based testing



$$H_0^B: (\boldsymbol{\beta}_P, \boldsymbol{\beta}_E)\left(\boldsymbol{\theta}_{\mathcal{P}}^\top, \boldsymbol{\theta}_{\mathcal{E}}^\top\right)^\top = \mathbf{0} \text{ vs } H_1^B: (\boldsymbol{\beta}_P, \boldsymbol{\beta}_E)\left(\boldsymbol{\theta}_{\mathcal{P}}^\top, \boldsymbol{\theta}_{\mathcal{E}}^\top\right)^\top \neq \mathbf{0} \text{ using } S_B$$

$$S_B = \mathbf{z}_{\text{AD}}^\top \left(\sum_{k=1}^{p+q} \mathbf{z}_{\text{xQTL(k)}} \mathbf{z}_{\text{xQTL(k)}}^\top \right) \mathbf{z}_{\text{AD}} \quad \text{and} \quad S_B \mid \mathbf{Z}_{\text{xQTL}} \sim \Gamma(\alpha_B^{\text{x}}, \xi_B^{\text{x}})$$

RESULTS



Physical protein-protein interactions with NTRK1

AD-associated

Not AD-associated



Mendelian Randomization replicates causality of *NTRK1* expression in cortex with AD



Counts of novel druggable genes associated with AD



NTRK1 inhibitor (GW441756)

Patient-derived iPSCs (P24 neurons)



Cleveland Clinic Lerner Research Institute — Genomic Medicine Institute

PRESENTER & CONTACT
Noah Lorincz-Comi, PhD
lorincn@ccf.org 440-821-0894

The Alzheimer's Cell Atlas | AlzGPS | AlzPipeline | AlzTarget | My Personal Mutanome

Cleveland Clinic Genome Center — Feixiong Cheng Lab

adsp Alzheimer's Disease Sequencing Project